CO5241279A1 - Vacuna - Google Patents
VacunaInfo
- Publication number
- CO5241279A1 CO5241279A1 CO00027742A CO00027742A CO5241279A1 CO 5241279 A1 CO5241279 A1 CO 5241279A1 CO 00027742 A CO00027742 A CO 00027742A CO 00027742 A CO00027742 A CO 00027742A CO 5241279 A1 CO5241279 A1 CO 5241279A1
- Authority
- CO
- Colombia
- Prior art keywords
- virus
- composition according
- adjuvant composition
- herpes simplex
- human
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000003308 immunostimulating effect Effects 0.000 abstract 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 abstract 1
- 241000588807 Bordetella Species 0.000 abstract 1
- 241000589968 Borrelia Species 0.000 abstract 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241000725619 Dengue virus Species 0.000 abstract 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
- 241000606790 Haemophilus Species 0.000 abstract 1
- 241000709721 Hepatovirus A Species 0.000 abstract 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 1
- 108010008707 Mucin-1 Proteins 0.000 abstract 1
- 241000204031 Mycoplasma Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000036673 PRAME Human genes 0.000 abstract 1
- 108060006580 PRAME Proteins 0.000 abstract 1
- 241000224016 Plasmodium Species 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 241000607142 Salmonella Species 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 241000223996 Toxoplasma Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000012737 microarray-based gene expression Methods 0.000 abstract 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000000813 peptide hormone Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición adyuvante que comprende una saponina y un oligonucleótido inmunoestimulante. Una composición adyuvante según la reivindicación 1 que comprende además un vehículo. Una composición adyuvante según la reivindicación 6, en la que el oligonucleótido inmunoestímulante contiene al menos dos repeticiones CG no metiladas estando separadas por 6 nucleótidos.Una composición de vacuna según la reivindicación 9, en la que dicho antígeno se deriva de un organismo seleccionado del grupo que comprende: Virus de la Inmunodeficiencia Humana, virus de la Varicela Zoster, Virus Herpes Simplex tipo 1, virus Herpes Simplex tipo 2, citomegalovirus humano, virus del Dengue, virus de la Hepatitis A, B, C o E, virus Respiratorio sincitial, virus del papiloma humano, Virus Influenza, Hib, virus de la meningitis, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Streptococcus, Mycoplasma, Mycobacteria, Haemophilus, Plasmodium o Toxoplasma, decapéptido de Stanworth; o antígenos asociados a tumores (TAA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, CEA, PSA, KSA o PRAME; o una hormona autopéptido, GnRH.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9908885.8A GB9908885D0 (en) | 1999-04-19 | 1999-04-19 | Vccine |
| US09/301,829 US6558670B1 (en) | 1999-04-19 | 1999-04-29 | Vaccine adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5241279A1 true CO5241279A1 (es) | 2003-01-31 |
Family
ID=10851789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00027742A CO5241279A1 (es) | 1999-04-19 | 2000-04-14 | Vacuna |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1905449A3 (es) |
| JP (1) | JP5307859B2 (es) |
| KR (1) | KR20020067617A (es) |
| CN (2) | CN1911443A (es) |
| AR (1) | AR023536A1 (es) |
| CO (1) | CO5241279A1 (es) |
| GB (1) | GB9908885D0 (es) |
| IL (2) | IL145982A (es) |
| MY (1) | MY127452A (es) |
| NO (1) | NO20110994L (es) |
| PL (2) | PL205547B1 (es) |
| SI (1) | SI1187629T1 (es) |
| ZA (1) | ZA200108619B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012022896A2 (pt) * | 2010-03-18 | 2018-03-27 | Novartis Ag | vacinas adjuvantes para meningococos do sorogrupo b |
| WO2012038801A1 (en) | 2010-09-21 | 2012-03-29 | National Institute Of Immunology | A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
| SG11201506727RA (en) * | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
| EP3078381A1 (en) * | 2015-04-10 | 2016-10-12 | Warszawski Uniwersytet Medyczny | Horse chestnut extract or escins for the treatment of alzheimer's disease |
| US11918646B2 (en) | 2017-12-11 | 2024-03-05 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| CN114767844A (zh) * | 2022-04-28 | 2022-07-22 | 泰州拜奥生物技术有限公司 | 一种水痘-带状疱疹病毒疫苗及其应用 |
| CN116159134A (zh) * | 2023-01-31 | 2023-05-26 | 四川大学 | 七叶皂苷和/或其盐化合物作为佐剂在疫苗中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
| CA2281838A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| WO1998056415A1 (en) * | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| BR9907691B1 (pt) * | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
| IL139813A0 (en) * | 1998-05-22 | 2002-02-10 | Loeb Health Res Inst At The Ot | Methods and products for inducing mucosal immunity |
| WO2000009159A1 (en) * | 1998-08-10 | 2000-02-24 | Aquila Biopharmaceuticals, Inc. | Compositions of cpg and saponin adjuvants and methods thereof |
| GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
| JP2003527352A (ja) * | 2000-01-13 | 2003-09-16 | アンティジェニクス インコーポレーテッド | Ｃｐｇおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法 |
| CA2396871A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
-
1999
- 1999-04-19 GB GBGB9908885.8A patent/GB9908885D0/en not_active Ceased
-
2000
- 2000-04-04 CN CNA200610100225XA patent/CN1911443A/zh active Pending
- 2000-04-04 CN CNB2005101096981A patent/CN100542606C/zh not_active Expired - Lifetime
- 2000-04-04 PL PL384582A patent/PL205547B1/pl unknown
- 2000-04-04 EP EP07121768A patent/EP1905449A3/en not_active Withdrawn
- 2000-04-04 PL PL384581A patent/PL203894B1/pl unknown
- 2000-04-04 SI SI200030557T patent/SI1187629T1/xx unknown
- 2000-04-04 KR KR1020017013357A patent/KR20020067617A/ko not_active Application Discontinuation
- 2000-04-04 EP EP20040076239 patent/EP1541170A1/en not_active Withdrawn
- 2000-04-14 CO CO00027742A patent/CO5241279A1/es not_active Application Discontinuation
- 2000-04-17 MY MYPI20001620A patent/MY127452A/en unknown
- 2000-04-18 AR ARP000101809A patent/AR023536A1/es not_active Application Discontinuation
-
2001
- 2001-10-16 IL IL145982A patent/IL145982A/en not_active IP Right Cessation
- 2001-10-19 ZA ZA200108619A patent/ZA200108619B/xx unknown
-
2008
- 2008-02-25 IL IL189736A patent/IL189736A0/en not_active IP Right Cessation
-
2011
- 2011-07-07 NO NO20110994A patent/NO20110994L/no not_active Application Discontinuation
- 2011-08-02 JP JP2011169244A patent/JP5307859B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739800A (zh) | 2006-03-01 |
| MY127452A (en) | 2006-12-29 |
| GB9908885D0 (en) | 1999-06-16 |
| EP1541170A1 (en) | 2005-06-15 |
| PL203894B1 (pl) | 2009-11-30 |
| CN100542606C (zh) | 2009-09-23 |
| EP1905449A2 (en) | 2008-04-02 |
| NO20110994L (no) | 2001-11-22 |
| IL145982A (en) | 2009-12-24 |
| ZA200108619B (en) | 2002-11-27 |
| JP2011241222A (ja) | 2011-12-01 |
| PL205547B1 (pl) | 2010-04-30 |
| EP1905449A3 (en) | 2009-03-25 |
| CN1911443A (zh) | 2007-02-14 |
| KR20020067617A (ko) | 2002-08-23 |
| SI1187629T1 (en) | 2005-04-30 |
| AR023536A1 (es) | 2002-09-04 |
| JP5307859B2 (ja) | 2013-10-02 |
| IL189736A0 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200838A1 (es) | Vacunas | |
| US6080725A (en) | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof | |
| ATE315405T1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| CA2370697A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
| JP2003519084A5 (es) | ||
| PE20011217A1 (es) | Composicion farmaceutica para modulacion inmunologica y preparacion de vacunas | |
| CO5241279A1 (es) | Vacuna | |
| EP1618889A3 (en) | Influenza Vaccine | |
| AR014181A1 (es) | Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados | |
| CA2268825A1 (en) | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates | |
| EA008741B1 (ru) | Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью | |
| HUP9900061A1 (hu) | Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók | |
| MX2022011159A (es) | Vacunas contra herpes zoster que comprende un agonista de tlr9. | |
| WO2002036790A3 (en) | Influenza virus vector for infection of dendritic cells | |
| HK1117729A1 (en) | Vaccines comprising mage antigen linked to protein d fragment | |
| ES2687288T3 (es) | Uso de un copolímero de bloques anfifílico no iónico tetrafuncional modificado por glicosilación como adyuvante inmunitario | |
| CA2488366A1 (en) | Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition | |
| Toyokuni et al. | Synthetic vaccines: I. Synthesis of multivalent Tn antigen cluster-lysyllysine conjugates | |
| Toth et al. | Recent advances in design and synthesis of self-adjuvanting lipopeptide vaccines | |
| AU2003229434A8 (en) | Cancer vaccines and methods of using the same | |
| JP2005532315A5 (es) | ||
| JP2018528188A (ja) | 細菌およびウイルスのワクチン戦略 | |
| CN101559225A (zh) | 脑膜炎球菌疫苗 | |
| MX2022011155A (es) | Inmunización activa de refuerzo contra tétanos, difteria y tosferina. | |
| Soleimani Roudi et al. | Vaccine adjuvants: Past, current and future |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |